Raghavan Chinnadurai

Abstract AMD3100 (Plerixafor) is being utilized in clinic for the mobilization of Hematopoietic Stem Cell (HSCs) from bone marrow into peripheral blood to facilitate peripheral blood sourced HSC transplantation. It is important to identify the immunomodulatory role of AMD3100 in bone marrow niche. We have investigated the effect of AMD3100 on culture expanded human bone marrow derived Mesenchymal Stem/Stromal Cells (BM MSCs) which are non-hematopoietic cells of the marrow niche.

Background and introduction Mesenchymal stromal cells (MSCs) are at the forefront of the cellular therapy revolution (1–3) whether for use in graft vs. host disease (GVHD) (4, 5), as a recently approved treatment of anal fistulas (6), or as an adjunct to CAR-T cell immunotherapy (7). There were over 1,240 clinical trials for MSCs between the years 2016 and 2020 highlighting their promise (8–11). Their potential was also recently realized in several COVID therapies (12–15).

Highlights • Host macrophages (Mφ) are indispensable for BM-MSC-dependent reduction of colitis • MSC-secreted chemokines CCL2 and CXCL12 synergistically induce M2 polarization • Host IL-10 competency is crucial for MSC-mediated recovery of DSS colitis • MSC-polarized host Mφ regulate IL-10 polarization by gut-bound lymphoid cells Summary Mesenchymal stromal cell (MSC)-based therapy for inflammatory diseases involves paracrine and efferocytotic activation of immunosuppressive interleukin-10+...